ADXS-31164

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameADXS-31164
Drug Alias NameADXS-HER2 construct vaccineLovaxin BLovaxin BADXS31-164ADXS-31164 +[10] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursBone Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesOS Therapies LLCOS Therapies Inc
Inactive CompaniesAyala Pharmaceuticals Inc
Active IndicationsBone Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A